Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
Portfolio Pulse from Vandana Singh
Agios Pharmaceuticals announced that the Phase 2 portion of the RISE UP study of mitapivat in sickle cell disease met its primary endpoint of hemoglobin response. The results support proceeding with the Phase 3 portion of the study. Agios plans to analyze the data further to select a dose for the Phase 3 study, which is expected to enroll 198 patients and report data in 2025.
June 26, 2023 | 4:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agios Pharmaceuticals' Phase 2 RISE UP study of mitapivat in sickle cell disease met its primary endpoint, supporting the progression to Phase 3. The company's stock price is down 1.38%.
The positive results from the Phase 2 RISE UP study indicate that Agios Pharmaceuticals' mitapivat has potential in treating sickle cell disease. This supports the progression to Phase 3, which could lead to eventual approval and commercialization of the drug. Although the stock price is currently down 1.38%, the positive news may lead to an increase in the short term as investors recognize the potential of the drug.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100